Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys 10,738 Shares of Stock

Anixa Biosciences, Inc. (NASDAQ:ANIXGet Free Report) Director Lewis H. Titterton, Jr. acquired 10,738 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was bought at an average price of $2.52 per share, with a total value of $27,059.76. Following the purchase, the director now directly owns 848,775 shares in the company, valued at approximately $2,138,913. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Anixa Biosciences Stock Up 0.8 %

ANIX stock opened at $2.64 on Thursday. The business has a 50 day moving average price of $2.89 and a 200 day moving average price of $3.55. The stock has a market cap of $84.51 million, a price-to-earnings ratio of -7.13 and a beta of 0.84. Anixa Biosciences, Inc. has a fifty-two week low of $2.21 and a fifty-two week high of $5.13.

Anixa Biosciences (NASDAQ:ANIXGet Free Report) last posted its earnings results on Tuesday, June 4th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. As a group, sell-side analysts anticipate that Anixa Biosciences, Inc. will post -0.44 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their target price on Anixa Biosciences from $12.00 to $7.00 and set a “buy” rating for the company in a research note on Monday.

View Our Latest Stock Report on Anixa Biosciences

Institutional Investors Weigh In On Anixa Biosciences

Institutional investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC increased its position in Anixa Biosciences by 274.6% during the fourth quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock worth $2,110,000 after buying an additional 39,820 shares during the period. Simplicity Wealth LLC acquired a new position in Anixa Biosciences during the first quarter worth approximately $44,000. Staley Capital Advisers Inc. acquired a new position in Anixa Biosciences during the first quarter worth approximately $31,000. Finally, Virtu Financial LLC increased its position in Anixa Biosciences by 47.2% during the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock worth $50,000 after buying an additional 5,183 shares during the period. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

(Get Free Report)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

Further Reading

Insider Buying and Selling by Quarter for Anixa Biosciences (NASDAQ:ANIX)

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.